Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving
to be effective at restoring T cell-mediated immune responses that can lead to marked and …

T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the
mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) …

Tumour-infiltrating lymphocytes are associated with a survival benefit in several tumour
types and with the response to immunotherapy,,,,,,–. However, the reason some tumours …

Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the
clinical care of patients with cancer. However, whether the T cell response to checkpoint …

The ability of the immune system to eliminate and shape the immunogenicity of tumours
defines the process of cancer immunoediting. Immunotherapies such as those that target …

New therapies that promote antitumour immunity have been recently developed. Most of
these immunomodulatory approaches have focused on enhancing T-cell responses, either …

The analysis of neoantigen-specific CD8+ T cells in tumour-bearing individuals is
challenging due to the small pool of tumour antigen-specific T cells. Here we show that mass …

Abstract PD-1 blockade unleashes CD8 T cells, including those specific for mutation-
associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit …

Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to
directly recognize and kill tumour cells,–. These strategies are limited by the emergence of …

Somatic gene mutations can alter the vulnerability of cancer cells to T-cell-based
immunotherapies. Here we perturbed genes in human melanoma cells to mimic loss-of …